Healthcare’s Once-in-a-Generation Disruption
The cost of healthcare in the United States continues to rise and the availability continues to decline. Healthcare spending accounts for 18% of U.S. GDP, and the costs in the U.S. are the highest in the world, increasing 130% in just the last decade. With this complexity comes an opportunity for entrepreneurs, innovators, and investors. iSelect is focused on finding technologies and innovations that reduce costs, increase accessibility, and improve quality of care.
iSelect Portfolio Companies
iSelect focuses on early-stage healthcare companies that are poised to help push the next healthcare revolution forward. We deliberately invest in companies that can make a positive impact on our society, as well as on the bottom line.
Cocoon Biotech, Inc.
Fibroin is an insoluble protein that is responsible for silk’s structure and tensile strength. Additional physical properties include tunable viscosity, anti-inflammatory, and wound healing attributes. Cocoon’s fibroin is expected to yield substantial improvements in use-cases such as bio-preservatives, drug or small/molecule delivery, natural lubricants, and hydrogels across numerous industries including human and animal health, agriculture, and consumer products. Learn more… 
Cofactor Genomics, Inc.
Cofactor Genomics is a precision medicine company that focuses on RNA for its understanding of disease – initially cancer but with applicability across many diseases. Learn more…
Entac Medical, Inc.
Entac Medical is developing noninvasive devices for predictive and diagnostic medicine based on a novel, patented, platform technology, Previs Audio Spectral Analysis. Their first product is used to predict post operative ileus after GI surgeries. Learn more…
Euclises Pharmaceuticals, Inc.
Euclises Pharmaceuticals is developing novel enzyme (COX-2) inhibitors designed to increase the effectiveness of chemotherapy safely Learn more…
Flywheel Exchange, LLC
Flywheel offers a SaaS platform that provides cloud-scale data management and computational analysis. Learn more…
GeneMatters, LLC
GeneMatters is a digital health platform that provides scalable, on-demand genetic counseling to meet the rapidly growing demand for genetic services. Learn more…
Gila Therapeutics, Inc.
Gila Therapeutics is developing a treatment for obesity using naturally occurring hormones known to induce satiety, leading to weight loss. Learn more…
Healionics, Inc.
Healionics, Inc. has developed a novel bio-material called STAR, that features strong anti-infective properties and significant reduction in the formation of scar tissue around implanted medical devices coated with the material. Learn more…
HepaTx Corp.
HepaTx has developed stem cell technologies that have the potential to drastically improve the life expectancy of patients with liver failure by providing a low-cost and scalable source of liver cells that can be used to preserve or regenerate liver function. Learn more…
Holobiome, Inc.
Holobiome is developing a platform for microbiome-based therapeutics to treat diseases of the central and enteric nervous systems. Learn more…
Immunophotonics, Inc.
Immunophotonics has developed a minimally invasive therapeutic cancer vaccine for the treatment of metastatic solid tumors. Learn more…
Indalo Therapeutics, Inc.
Indalo is a pharmaceutical company developing life-changing treatments for fibrotic diseases. Learn more…
MOBILion Systems, Inc.
MOBILion Systems is an analytical instrumentation company using ion mobility to substantially improve the ability to see and identify previously undetectable, clinically significant molecules in minutes. Learn more…
Molecular Assemblies
Molecular Assemblies is developing an enzymatic DNA synthesis platform technology. Molecular Assemblies’ novel enzymatic DNA synthesis platform has the potential to fundamentally transform how we write genetic building blocks with applications across food, healthcare, energy, and beyond. Learn more…
Neuros Medical, Inc.
Neuros Medical, a medical device company, develops an electrical nerve block to treat chronic pain for conditions including neuroma/residual limb pain and chronic post-surgical pain. Learn more…
Nix, Inc.
Nix Biosensors is developing a wearable device and biosensor system platform that monitors hydration in real-time, helping reduce health incidents associated with dehydration while improving performance for athletes, laborers, military personnel and the elderly. Learn more…
Readout
Readout (or The Company) has developed a low-cost breath-analysis device with clinical grade accuracy for measuring blood-ketone levels, an important indicator of a patient’s metabolism. Learn more…
SciBac, Inc.
SciBac is developing a platform technology called MERGE that enables the Company to efficiently combine desired traits of two microbes into one stable hybrid organism through lab-induced directed evolution. Learn more…
Shield Bio, Corp.
Shield Diagnostics Corp. (Shield Diagnostics or ‘The Company’) has developed a proprietary genotyping platform technology that substantially reduces the time and cost of genetic testing while maintaining the highest degree of accuracy. Depending on the comparative test, the Company’s technology can achieve a 16-500x improvement on cost and an 8-16x hourly reduction in time while maintaining 99.5% accuracy. The company drives down cost and increases efficiency by combining three core technologies: high-density/reusable arrays, custom phosphoramidite chemistry and a fully automated and customized microfluidics system. Shield Diagnostics’ competitors have business models built on individual tests that generate revenue from consumables. Since Shield Diagnostics has the ability to run multiple tests on reusable components, it can reduce costs and scale volume at levels not achievable by the competition. Shield Diagnostics’ platform technology has applicability across a variety of sample types (blood, urine, saliva, plant & animal samples) and industries. Shield Diagnostics will enter the market in 2H 2018 as a CLIA approved laboratory developed test (LDT), allowing them to bypass the lengthier process required for PMA or 510k approval. The company plans to first target the $28 billion sexually transmitted infection (STI) market, representing 20 million new STI infections each year. Potential future applications include low-cost, blood-based cancer diagnostic testing, infectious disease testing for tuberculosis & MRSA, animal breeding optimization, plant genotyping, and direct-to-consumer genetic testing. Shield Diagnostics is raising $6 million in Series A preferred equity at a $15 million pre-money valuation co-led by Andreesen Horowitz and Refactor Capital. Proceeds from the Series A round will be used to build out their S&M and R&D teams, R&D associated expenses, and laboratory operations. Learn more…
Meet Our Selection Committee
Our Healthcare Selection Committee consists of industry and subject matter experts who help guide iSelect’s investment decisions. With firsthand experience and a true pulse on the industry, we consider these individuals key to our success in finding and investing in healthcare innovation.
Tiffany Osborn holds a Bachelor’s of Science Degree in Biology with a minor in Chemistry from University of Houston in Houston, Texas. She earned her medical degree from University of Texas Health Science Center in…
Ruchir Sehra, M.D., is a medtech executive with extensive experience in early (private), mid (public), and late stage (acquisition) medical device companies in various health and disease areas. Dr. Sehra currently serves as the CEO…
Surekha Trivedi is VP Strategic Development at Danaher. She is a Senior Strategy, M&A, and Product Development Executive with a deep understanding of the life sciences, diagnostics, and healthcare markets. Recognized as a strategy expert…
Jill Davies is Co-Founder and Chief Executive Officer for GeneMatters. Jill has more than 20 years’ experience in the genetics field, with leadership in clinical services, telehealth, product development, business development and operations. Prior to…
Vice President of Research at Matatu, Nathan McNulty is microbiologist with a passion for addressing complex problems in healthcare, nutrition, and agriculture using innovative technologies, carefully conducted science, and teamwork.
Jin-Moo Lee, MD, PhD, is Professor of Neurology, Radiology, and Biomedical Engineering; and Head of the Cerebrovascular Disease Section in the Department of Neurology; Co-Director of the Stroke and Cerebrovascular Center at Barnes-Jewish Hospital/Washington University….
Emily Fassi is a board-certified genetic counselor with experience counseling adults and children about genetic diagnoses and predisposition to genetic conditions. She currently works at the Mountain States Tumor Institute with patients who have a…
Dr. David Messina has spent the last 20 years in computational biology and genetics. He worked on the Human Genome Project at Washington University in Saint Louis, mapped disease genes at the University of Chicago,…
Dr. Bruce German is a Professor and Chemist of Food Science and Technology at the University of California, Davis and researches the role of fats and other components in the diet. He develops ways to…
Jean Roberson is CFO of Appistry, a big data analytics company focused on supporting precision medicine and next generation healthcare. She has over 25 years of experience in all areas of finance from early-stage venture-funded…
A regulatory professional with over 27 years of experience in the medical products industry, Melissa currently serves as Founder, President and CTO at Graematter, Inc. and Senior VP Regulatory at Topera. Specialties include regulatory intelligence research and reporting,…
Andy Daniels is a seasoned business executive and successful entrepreneur, an active angel investor, and serves on multiple governing boards with companies in the areas of venture capital, wealth management, agriculture, healthcare, technology innovation, commodity…
Dr. Paul D. Olivo, M.D., Ph.D., has been the Chief Scientific Officer of Apath, LLC since 2000 and served as its President. Dr. Olivo is an Entrepreneur-in-Residence at BioGenerator, where he previously served as a…
Bobby Sandage is currently President and CEO of Euclises, Chairman of the Board of Immunophotonics, member of the board of directors of EDIS, and a member of the Cultivation Capital life sciences fund investment committee. He was…
Lila Solnica-Krezel is professor and head of Developmental Biology at Washington University St. Louis, School of Medicine. She is currently investigating the cellular and molecular genetic mechanisms underlying vertebrate gastrulation, which has practical significance in…
Gian Cavallini oversees the development and execution of Advanced ICU Care’s medical staffing growth strategy and leads the implementation of various initiatives to position the company for continued growth. His expertise in development and operations,…
Mr. Don Imholz is a business executive/leader with diverse experience in Operations and IT, extensive Board involvement, and a strong track record of creating sustainable competitive advantage. His expertise in cybersecurity, big data, digital transformation,…
Presently leading Arch Cancer Care as Medical Director, Dr. Beat is a local expert in collaborative prostate cancer management. At a national level, he contributes to physician leadership committees within the US Oncology Network. Having earned an executive…
Mr. Beuttenmuller possesses over 30 years experience in Corporate Finance with Emerson Electric, Esse Health, Essence Healthcare and Innovare. He is experienced in financial analysis, risk management, mergers and acquisitions, new business development, start-ups, strategic…
Professor of Internal Medicine – Hematology, Oncology and Blood and Marrow Transplantation at UUniversity of Iowa Roy J. and Lucille A. Carver College of Medicine and former Professor of Medicine and Genetics at Washington University…
Dr. John Talley, Chief Science Officer for Euclises Pharmaceuticals and SARmont, brings over thirty years experience and a record as one of the world’s most successful medicinal chemists. He is best known as the co-inventor…
Dr. Rutter is founder and CEO of Metaphase Design Group, a design firm serving industrial, commercial and consumer product and packaging clients internationally. He is an acknowledged specialist in ergonomic product design and a leading…
Mark has served as ProteoSense’s CEO since 2013. Previously, Mark served as CEO/COO of several startups, including Assurex Health (2006-09). Mark earned a B.S. in Electrical Engineering from the Univ. of Dayton and an M.S….
Dr. Panagos is a Professor of Emergency Medicine and Neurology at Washington University in St Louis. He is a 1987 graduate of Dartmouth College. In 1994, he completed his medical education at Emory University. Following…
Before joining OTMIR in 2016, Brian Buntaine worked for more than 15 years in the life sciences industry. He began his career as a lab manager at Washington University in St. Louis. In 2003, Brian joined…
Dr. Raghavan brings several years of experience managing preclinical safety and efficacy studies for biologicals and small molecule therapeutics and managing strategic alliances with biotech and pharmaceutical companies. His expertise includes postdoctoral research in opioid…
Edwards was employed for 42 years in the pharmaceutical and life sciences arenas. From 1990 to 2010, he held Regulatory Affairs positions of increasing responsibility at TAP/Takeda Global Research & Development Center, Lake Forest, Illinois. …
Michael Nichols, Ph.D. presently serves as an investor and C level management for various startups. He serves as an Analyst for Vinlogx, a platform that acquires, stores, and analyses internal vehicle information enabling solutions across…
David Christenson joined BioGenerator as an Entrepreneur-in-Residence in 2015 focusing primarily on healthcare and specifically in information technology, care delivery and payment, and services. Over a 30-year career, David has developed a substantive background in…
Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine
An accomplished senior executive with start-ups, growth, and turn-around organizations, Renato developed a healthcare technology corporation, HealthTech Solutions, from a small start-up of 3 people to a national provider of technical solutions to health care…
Resources and News
How Shifting Spending to Healthy Foods Could Prevent Chronic Illness
The burden of chronic health issues is massive: 90% of the nation’s $3.3 trillion in annual health care expenditures are for people with chronic and mental illness, according to the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). Even...
Solving the Public Health Crisis by Making Healthy Nutrition as Addictive as Sugar
The modern world has a serious problem with sugar. The average American consumes more than 129 pounds of the stuff each year, according to the USDA, more than double what we ate two generations ago. And, unlike in previous decades when most sweeteners came from cane...
This Rare Disease Day, Let’s Do More
There are some 7,000 known rare diseases in the world today and they affect an estimated 25-30 million people in the United States alone. This day, celebrated every year on February 28th, holds special significance to me because my six-year-old son is one of the 1 in...
Are We Really Ready for Genetic Testing?
There’s a lot we still don’t know about the power of genetic testing. For one thing, it’s becoming more powerful than ever expected. Already, patients can get gene-based information about their cancer risk, for instance, as well as details about genetic disorders that might impact their children, autism diagnoses, and more.
Enabling the Next Generation of Healthcare IT
It’s been a long time coming, but technology is finally transforming the healthcare industry, enabling functions and services that were all but unimaginable just a few years ago. Case in point: data.
Who Has Your DNA? Why Data Privacy Is the Next Battleground in Consumer Genetics
Genetics is changing the world as we know it, and not only in the realm of healthcare and medical science. Whether it’s 23andMe delivering specific details about our ancestry, genetic science being used to united people who have been switched at birth, or even DNA information being used to catch the Golden State Killer, there is much that genomics can now accomplish.
Humanity Is Dehydrated, and It Doesn’t Even Know It Yet
One thing is for sure: we’re not drinking enough water. None of us. And it’s damaging our health. That was the message of a recent article in The New York Times.
Dehydration Nation: Preventing One of the Most Common Health Risks in Real-Time
Up to three-fourths of Americans are chronically dehydrated, and the condition can be far more debilitating than it might seem. Mild dehydration — literally, not drinking enough water on a day-to-day basis — can impair cognitive performance by up to 20%, affecting reaction time, mental accuracy and memory. More severe cases, however, can result can result in seizures, brain damage, shock, and death.
RNA Is Becoming the New DNA, Opening New Doors in Medicine
If a person’s DNA is the roadmap of their lifetime health, their RNA is more of a real-time barometer, recording what happens in their body on a minute-by-minute basis. Our DNA stores and transfers genetic information, but remains little changed throughout our lives. At best, it can tell us about the probability we will someday develop various diseases — whether or not we will get cancer, for instance, or be susceptible to diabetes or heart disease — but it can’t tell us much about our current health.
Flywheel: Accelerating Discoveries By Creating an App Store for Science
Flywheel is building an archive of scientific developments, methods and tools so that future researchers will be able to build on those discoveries.
GeneMatters: How Genetic Testing Is Pushing Us Toward Medicine’s Next Frontier
Genetic testing has gone mainstream — consider examples like 23andMe and even Ancestry.com, which both offer genetic analysis by mail — and the market is on track to exceed $10 billion in the next several years.
What iSelect Is Looking For in the Companies It Invests In
So people ask me what the optimal, or perfect, iSelect investment opportunity looks like. And there's a scientific, or a finance type of answer that I can give you that we're looking for a company that has an opportunity to have a 10 times return to our investor, or...
